Abstract:Epilepsy Currents, Ahead of Print. Prevalence and Risk Factors for Pharmacoresistance in Children With Focal Cortical Dysplasia-Related Epilepsy Cohen NT, Chang P, You X, Zhang A, Havens KA, Oluigbo CO, Whitehead MT, Gholipour T, Gaillard WD. Neurology. 2022;99(18):e2006-e2013. doi:10.1212/WNL.0000000000201033 Background and objectives:Focal cortical dysplasia is the most common cause of surgically-remediable epilepsy in children. Little is known about the risk factors for the timing and development of pharmacoresistance in this population. This study sought to evaluate the prevalence and risk factors for pharmacoresistance in pediatric FCD-related epilepsy.Methods:In this retrospective single-center cohort design, patients were identified from search of centralized radiology report database and a central epilepsy surgical database. Inclusion criteria consisted of: 3T MRI-confirmed FCD from January, 2011 to January, 2020; ages 0 days to 22 years at MRI; at least 18 months of documented follow-up after MRI, unless had single seizure or incidentally discovered FCD. Records were excluded if there was dual pathology (except for mesial temporal sclerosis), hemimegalencephaly, or tuberous sclerosis complex present in imaging or history.Results:One hundred forty-three patients with confirmed FCD met inclusion criteria. One hundred twenty-four children had epilepsy (87% of FCD patients) with median age of seizure onset 2.7 years (IQR 0.75-6 years, range 0 to 17 years). Twelve children (8.5%) had a single lifetime seizure (provoked or unprovoked) or recurrent provoked seizures. Seven children (4.9%) had incidental FCD. Ninety-two patients (74%) of those with epilepsy met criteria for pharmacoresistance. Of children with epilepsy of all types, 93 children (75%) were seizure-free at the last visit. Eighty-two patients underwent epilepsy surgery, of whom 59 (72%) achieved seizure freedom. 7% (9/124) achieved seizure freedom with a second ASM, and 5.6% (7/124) with a third or more ASMs. Failure of only one antiseizure medication is associated with enormous increased incidence and earlier development of pharmacoresistance (OR 346, 95% CI 19.6-6100). Cox regression showed FCD lobar location, pathologic subtype, and age of seizure onset are not.Conclusions:Failure of one antiseizure medication is associated with substantial risk of pharmacoresistance. These data support an operational re-definition of pharmacoresistance, for surgical planning, in FCD-related epilepsy to the failure of one antiseizure medication, and support early, potentially curative surgery to improve outcomes in this patient population.

Drug Resistance in Cortical and Hippocampal Slices from Resected Tissue of Epilepsy Patients: No Significant Impact of P-Glycoprotein and Multidrug Resistance-Associated Proteins

Surgical Treatment for Drug-Resistant Epilepsy Due to Early Brain Injury in Children

Expressions of drug-resistance related genes and the significance in sclerotic hippocampi from patients with drug-resistant mesial temporal lobe epilepsy

Neuroimaging of drug resistance in epilepsy

The transport of antiepileptic drugs by P-glycoprotein.

Subicular Pyramidal Neurons Gate Drug Resistance in Temporal Lobe Epilepsy

P-glycoprotein Alters Blood–brain Barrier Penetration of Antiepileptic Drugs in Rats with Medically Intractable Epilepsy

Proteomic Differences in the Hippocampus and Cortex of Epilepsy Brain Tissue

Multidrug Resistance-Associated Protein 1 Decreases the Concentrations of Antiepileptic Drugs in Cortical Extracellular Fluid in Amygdale Kindling Rats

Combined effects of epileptic seizure and phenobarbital induced overexpression of P-glycoprotein in brain of chemically kindled rats.

Inhibition of epileptiform activity by neuropeptide Y in brain tissue from drug-resistant temporal lobe epilepsy patients

Effect of 21-Day Exposure of Phenobarbital, Carbamazepine and Phenytoin on P-glycoprotein Expression and Activity in the Rat Brain

The Study of Expression of P-glycoprotein in Hippocampus in a Chronic Epileptic SD Rat Model

Intractable Epilepsy and the P-glycoprotein Hypothesis

Testing Association of Rare Genetic Variants with Resistance to Three Common Antiseizure Medications.

Lesional Epilepsy in Children: Removing Doubt to Cut It Out

Resective Epilepsy Surgery and Respective Histopathological Diagnoses: A Retrospective Cohort Study

The Concept of Drug-Resistant Epileptogenic Zone

High concordance between hippocampal transcriptome of the mouse intra-amygdala kainic acid model and human temporal lobe epilepsy

Glutathione S-transferase π, DNA topoisomeraseⅡ, and P-glycoprotein expression in brain of patients with refractory epilepsy

Recurrent epileptiform discharges in the medial entorhinal cortex of kainate-treated rats are differentially sensitive to antiseizure drugs